Karim, S. S. A., & Karim, Q. A. (2021). Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(21)02758-6

Varmus, H. (2021, August 31). Covid has revealed the need for genomic sequencing around the world. Financial Times. https://www.ft.com/content/342fd3c3-5a22-49a0-9cef-135f2ccd8700

Torjesen, I. (2021). Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ, 375, n2943. https://doi.org/10.1136/bmj.n2943

Smith, L., Potts, H., Amlôt, R., Fear, N. T., Michie, S., & Rubin, J. (2022). How has the emergence of the Omicron SARS-CoV-2 variant of concern influenced worry, perceived risk, and behaviour in the UK? A series of cross-sectional surveys. OSF Preprints. https://doi.org/10.31219/osf.io/rpcu2

Hamblin, J. (2021, December 9). Perspective | Omicron won’t keep us from ending the pandemic. We’re doing that ourselves. Washington Post. https://www.washingtonpost.com/outlook/2021/12/09/omicron-coronavirus-individual-threat/

SARS-CoV-2 variants of concern and variants under investigation. (2021). 45.

Le Page, M. (2021, November 22). What we know so far about AY.4.2 and other new coronavirus variants. New Scientist. https://institutions.newscientist.com/article/2298363-what-we-know-so-far-about-ay-4-2-and-other-new-coronavirus-variants/?utm_campaign=echobox&utm_medium=social&utm_source=Twitter

Prof. Christina Pagel. (2021, December 29). Omicron was dominant everywhere in England by Christmas https://t.co/x58pJi7VcD [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1476161382852796419

Pan-Hammarström lab. (2022, January 7). Our new study: Heterogeneous vaccination strategy with inactivated vaccine + mRNA booster elicits strong B and T cell response against the WT and VOC including Omicron @VirusesImmunity https://t.co/aBiN9anMBL [Tweet]. @panhammarstrom. https://twitter.com/panhammarstrom/status/1479449892410044419

Wong, S.-C., Au, A. K.-W., Chen, H., Yuen, L. L.-H., Li, X., Lung, D. C., Chu, A. W.-H., Ip, J. D., Chan, W.-M., Tsoi, H.-W., To, K. K.-W., Yuen, K.-Y., & Cheng, V. C.-C. (2022). Transmission of Omicron (B.1.1.529) - SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: A challenge of elimination strategy of COVID-19. The Lancet Regional Health – Western Pacific, 18. https://doi.org/10.1016/j.lanwpc.2021.100360

Kirby, J. (2021, December 23). Omicron collides with a struggling global vaccination campaign. Vox. https://www.vox.com/22846774/omicron-global-vaccines-covronavirus-covid-19

Zuo, F., Abolhassani, H., Du, L., Piralla, A., Bertoglio, F., Campos-Mata, L. de, Wan, H., Schubert, M., Wang, Y., Sun, R., Cassaniti, I., Vlachiotis, S., Kumagai-Braesch, M., Andréll, J., Zhang, Z., Xue, Y., Wenzel, E. V., Calzolai, L., Varani, L., … Pan-Hammarström, Q. (2022). Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant (p. 2022.01.04.22268755). https://doi.org/10.1101/2022.01.04.22268755

Geddes, L., & correspondent, L. G. S. (2022, January 11). Will Covid-19 become less dangerous as it evolves? The Guardian. https://www.theguardian.com/world/2022/jan/11/will-covid-19-become-less-dangerous-as-it-evolves

Harry Spoelstra. (2021, November 26). Breaking: ECDC has designated B.1.1.529 today as a #VOC https://t.co/WyLnc9xUoJ [Tweet]. @HarrySpoelstra. https://twitter.com/HarrySpoelstra/status/1464261361370910721

World Health Organization (WHO). (2021, December 2). Dr @mvankerkhove updates on what we know so far about the new #COVID19 variant of concern, Omicron ⬇️ https://t.co/43jqMUotrX [Tweet]. @WHO. https://twitter.com/WHO/status/1466376465990180864

Roessler, A., Riepler, L., Bante, D., Laer, D. von, & Kimpel, J. (2021). SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals (p. 2021.12.08.21267491). https://doi.org/10.1101/2021.12.08.21267491

Wheatley, A. K., & Juno, J. A. (2021). COVID-19 vaccines in the age of the delta variant. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00688-5

Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Murugesan, D. R., Desiraju, B. K., Kshetrapal, P., Pandey, R., Scaria, V., Malik, P. K., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00680-0

Kit Yates. (2021, November 26). European centres for disease prevention and control has designated B.1.1.259 as a variant of concern. Fast work. Https://t.co/f6JiWVvjJC [Tweet]. @Kit_Yates_Maths. https://twitter.com/Kit_Yates_Maths/status/1464285136137170947

Sett, S., Ribeiro, C. dos S., Prat, C., Haringhuizen, G., Avšič, T., Batten, C., Beato, M. S., Bourhy, H., Caro, A. D., Charrel, R., Coutard, B., Drexler, J. F., Drosten, C., Fooks, A. R., Klempa, B., Koopmans, M., Klimkait, T., Günther, S., Manuguerra, J.-C., … Scholz, A. H. (2021). Access and benefit-sharing by the European Virus Archive in response to COVID-19. The Lancet Microbe, 0(0). https://doi.org/10.1016/S2666-5247(21)00211-1

Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021). Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Science Immunology. https://doi.org/10.1126/sciimmunol.abl4509

Kraemer, M. U. G., Hill, V., Ruis, C., Dellicour, S., Bajaj, S., McCrone, J. T., Baele, G., Parag, K. V., Battle, A. L., Gutierrez, B., Jackson, B., Colquhoun, R., O’Toole, Á., Klein, B., Vespignani, A., COVID-19 Genomics UK (COG-UK) Consortium‡, Volz, E., Faria, N. R., Aanensen, D. M., … Pybus, O. G. (2021). Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. Science, 373(6557), 889–895. https://doi.org/10.1126/science.abj0113

Shapiro, J., Dean, N. E., Madewell, Z. J., Yang, Y., Halloran, M. E., & Longini, I. (2021). Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and Reports [Preprint]. Epidemiology. https://doi.org/10.1101/2021.05.20.21257461